Radiological evaluation of tumor response in oncological studies (tumor response evaluation);Radiologische Evaluation des Tumoransprechens in onkologischen Therapiestudien (Tumor Response Evaluation)

RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren

Volumn 183, Issue 8, 2011, Pages 695-703

  Gebauer, B ^a   Bohnsack, O ^b   Riess, H ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b PAREXEL INTERNATIONAL   (United States)

Author keywords

CT; MR imaging; neoplasms; oncology; Response evaluation; treatment effects

Indexed keywords

ARTICLE; CANCER THERAPY; CLINICAL EVALUATION; LYMPH NODE; ONCOLOGY; PRIORITY JOURNAL; RADIOLOGIST; RADIOLOGY; RESEARCH; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; COOPERATIVE BEHAVIOR; DISEASE PROGRESSION; ENDPOINT DETERMINATION; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INTERDISCIPLINARY COMMUNICATION; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 79961029591     PISSN: 14389029     EISSN: 14389010     Source Type: Journal    
DOI: 10.1055/s-0029-1246074     Document Type: Article

References (26)

1. Johnson J R., Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 2003 21 1404-1411 (Pubitemid 46606423)
2. WHO Handbook for reporting results of cancer treatments. Geneva 1979
3. Miller A B., Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981 47 207-214 (Pubitemid 11167383)
4. Ng J K., Urbanski S J., Mangat N et al. Colorectal liver metastases contract centripetally with a response to chemotherapy: a histomorphologic study. Cancer 2008 112 362-371
5. Therasse P, Arbuck S G., Eisenhauer E A. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000 92 205-216
6. Cheson B D., Horning S J., Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkins lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999 17 1244
7. Cheson B D., Pfistner B, Juweid M E. et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007 25 579-586 (Pubitemid 350002966)
8. Macdonald D R., Cascino T L., Schold S C. et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990 8 1277-1280 (Pubitemid 20195640)
9. Blade J Jr, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998 102 1115-1123 (Pubitemid 28435189)
10. Byrne M J., Nowak A K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004 15 257-260 (Pubitemid 38262625)
11. Durie B G., Harousseau J L., Miguel J S. et al. International uniform response criteria for multiple myeloma. Leukemia 2006 20 1467-1473 (Pubitemid 44264086)
12. Eisenhauer E A., Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009 45 228-247
13. Schwartz L H., Bogaerts J, Ford R et al. Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer 2009 45 261-267
14. Choi H, Charnsangavej C, Faria S C. et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007 25 1753-1759 (Pubitemid 46797957)
15. Bruix J, Sherman M, Llovet J M. et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001 35 421-430 (Pubitemid 32844200)
16. Llovet J M., Di Bisceglie A M., Bruix J et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008 100 698-711
17. Llovet J M., Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008 359 378-390
18. Young H, Baum R, Cremerius U et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999 35 1773-1782 (Pubitemid 29512308)
19. Wahl R L., Jacene H, Kasamon Y et al. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009 50 Suppl 1 122S-150S
20. Verbraecken J, Van de Heyning P, De Backer W et al. Body surface area in normal-weight, overweight, and obese adults. A comparison study. Metabolism 2006 55 515-524
21. Turkbey B, Albert P S., Kurdziel K et al. Imaging localized prostate cancer: current approaches and new developments. Am J Roentgenol 2009 192 1471-1480
22. Hein P A., Romano V C., Rogalla P et al. Linear and volume measurements of pulmonary nodules at different CT dose levels intrascan and interscan analysis. Fortschr Röntgenstr 2009 181 24-31
23. Kalkmann J, Ladd S C., Greiff A de et al. Suitability of semi-automated tumor response assessment of liver metastases using a dedicated software package. Fortschr Röntgenstr 2010 182 581-588
24. Puesken M, Juergens K U., Edenfeld A et al. Einfluss des Vaskularisationsgrades auf die automatische Segmentierung und Messung von Lebertumoren nach RECIST in einer biphasischen Multi-Slice-CT (MSCT). Fortschr Röntgenstr 2009 181 67-73
25. Perceptive Informatics. Berlin 2010 http://www.recist.com/ [updated 21.12.2010; cited 21.12.2010]
26. Lencioni R, Llovet J M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010 30 52-60